Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bausch Agrees $300m Glumetza Antitrust Settlement As Lupin Awaits Trial

Lupin Set To Face Trial Over Allegations In October 2021

Executive Summary

Bausch Health, which rebranded from Valeant Pharmaceuticals following a list of controversies, has reached a proposed settlement deal worth $300m to resolve claims it paid off ANDA sponsor Lupin to delay generic entry for a generic to its Glumetza brand, paving the way for an extraordinary price hike.

You may also be interested in...

Philip Morris Closes In On Vectura As £1.1bn Offer Passes Threshold

Philip Morris once again pledged to up R&D in Vectura after its £1.1bn takeover offer for the UK-based inhalation specialist became unconditional, following the tobacco giant’s acrimonious face-off with private equity Carlyle earlier this year.

Lupin Reaches Quarter-Of-A-Billion Dollar Deal Over Glumetza Antitrust Claims

Lupin has agreed to pay $248m to settle the majority of antitrust claims against the company alleging that it caused and enabled the prolonged delayed launch of generic Glumetza, which subsequently saw a price hike of more than 800% by originator Valeant, now Bausch Health.

Samsung Bioepis Boasts Positive Data On Lucentis And Herceptin Biosimilars

Ahead of launching potentially its Lucentis biosimilar in the EU early next year, Samsung Bioepis has reported two lots of positive analysis involving its Byooviz biosimilar, at the same time as it disclosed the findings of a five-year follow-up study for its trastuzumab biosimilar, Ontruzant.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts